Posters

      Estimation Of Smoking Cessation Benefits On Cardiovascular Risk Via Lipidomics And Transcriptomics Analysis Of Apoe-/- Mice Liver

      Boue, S.; De Leon, H.; Lebrun, S.; Peitsch, M. C.; Hoeng, J.
      Conference date
      Jun 2, 2013
      Conference name
      The 81st European Atherosclerosis Society (EAS) Congress
      Link to more information
      Link to more information
      Topic
      Summary

      Aim: We investigated the effect of mainstream cigarette smoke (CS) exposure and a protocol of discontinuation of smoke exposure mimicking smoking cessation on liver lipid and transcriptome profile in the ApoE-/- mouse, a well-established model for human atherogenesis. Methods: Livers obtained from ApoE-/- mice exposed to either (i) mainstream smoke of the 3R4F reference research cigarette for six months (CS), (ii) fresh air for six months (sham), or (iii) CS for 3 months followed by fresh air for 3 months (cessation), were extracted for lipids using a robotic-assisted method and analyzed on six different mass spectrometric platforms. Targeted and non-targeted mass spectrometry methods allowed quantification of more than 200 lipid species. In addition, the liver transcriptome was profiled on Affymetrix GeneTitan:GeneChip® HT mg-430 PM plates. Results: In liver, exposure to cigarette smoke elevated several lipid species including free and esterified cholesterol, triacylglycerols, phospholipids, sphingomyelins, and ceramides. The concentration of triacylglycerols further increased upon smoke exposure cessation, correlating with the increase of body weight, whereas the concentration of phosphatidylglycerols and sphingomyelins was reduced. Gene set enrichment analysis of the transcriptomes between the 3 conditions revealed biological functions that are regulated by CS exposure in the liver of ApoE-/- mice: glutathione metabolism (detoxification), oxidoreduction (energy), coenzyme biosynthesis, phosphorus metabolic process and lipid biosynthesis. The enrichment of these gene sets was clearly reduced in the cessation setup. Conclusions: Coupled investigation of detailed lipidomics and transcriptomics profiles, taking into account co-factors such as total body weight and body weight progression in the weeks before profiling, enabled to highlight, in a mouse model of atherogenesis, lipid species which are differentially regulated by cigarette smoke exposure and upon smoking cessation.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.